Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression

International Journal of Neuropsychopharmacology

Volumn 19, Issue 4, 2016, Pages

  Udina, M ^a   Navines R ^a,b,d   Egmond, E ^a,d   Oriolo, G ^a,c   Langohr, K ^e   Gimenez, D ^d   Valdes M ^a,c   Gomez Gil E ^a   Grande, I ^a,b   Gratacos M ^f   Kapczinski, F ^g   Artigas, F ^b,h   Vieta, E ^a,b,c   Sola R ^d   Martin Santos R ^a,b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^f Barcelona Biomedical Research Park   (Spain)

^g HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^h INST D INVESTIGACIONS B   (Spain)

Author keywords

5HT1A; COMT; depression; GCR1; genetic; hepatitis C; inflammation pathways; personality traits; risk factors

Indexed keywords

ALPHA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; FK 506 BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; SEROTONIN; SEROTONIN RECEPTOR; ANTIVIRUS AGENT; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; COMT PROTEIN, HUMAN; HTR1A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INTERLEUKIN DERIVATIVE; SEROTONIN 1A RECEPTOR; TACROLIMUS BINDING PROTEIN 5;

ADULT; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; DEPRESSION; DISEASE ASSOCIATION; DSM-IV; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL FUNCTION ASSESSMENT; MENTAL PATIENT; NEUROTRANSMISSION; PATIENT HEALTH QUESTIONNAIRE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; TEMPERAMENT AND CHARACTER INVENTORY; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; DEPRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, GLUCOCORTICOID; RIBAVIRIN; TACROLIMUS BINDING PROTEINS; TREATMENT OUTCOME;

EID: 84966331023     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv135     Document Type: Article

References (82)

1. Albert PR, Le Francois B, Millar AM (2011) Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Mol Brain 4:21-35.
2. Anisman H (2009) Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 34:4-20.
3. Asnis GM, De La Garza R, 2nd (2006) Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40:322-335.
4. Buskila D, Cohen H, Neumann L, Ebstein RP (2004) An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9:730-731.
5. Cai W, Khaoustov VI, Xie Q, Pan T, Le W, Yoffe B (2005) Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 42:880-887.
6. Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226-238.
7. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003) Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psych 160:1342-1345.
8. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH (2012) Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 69:1044-1053.
9. Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R (2013) A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 59:926-933.
10. Castellvi P, Navinés R, Gutierrez F, Jiménez D, Márquez C, Subirà S, Solà R, Martín-Santos R (2009) Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. J Clin Psychiatry 70:817-828.
11. Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18-21.
12. Cloninger CR, Svrakic DM (1997) Integrative psychobiological approach to psychiatric assessment and treatment. Psychiatry 60:120-141.
13. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975-990.
14. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821.
15. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831-10843.
16. Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer RL (2001) Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom Med 63:679-686.
17. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446-457.
18. Ermis F, Senocak Tasci E (2015) New treatment strategies for hepatitis C infection. World J Hepatol 7:2100-2109.
19. Evans DL et al. (2005) Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58:175-189.
20. Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, Restrepo C, Lopez JC, García-Álvarez M, Miralles P, Soriano V, Benito JM, Resino S (2013) Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. AIDS 27:163-1673.
21. First MB, Spitzer RL, Williams JB (1995) Structured clinical interview for DSM-IV (SCID-I): User's guide and interview, research version. New York: Biometrics Research Department, New York Psychiatric Institute.
22. Fransen Van De Putte DE, Fischer K, Posthouwer D, Van Erpecum K, Mauser-Bunschoten EP (2009) Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study. Haemophilia 15:544-551.
23. Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, Laor N, Rauchverger B, Kreinin A, Poyurovsky M, Schneidman M, Modai I, Weizman R (1999) Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry 4:389-392.
24. Galecka E, Szemraj J, Bienkiewicz M, Majsterek I, Przybylowska-Sygut K, Galecki P, Lewinski A (2013) Single nucleotide polymorphisms of NR3C1 gene and recurrent depressive disorder in population of Poland. Mol Biol Rep 40:1693-1699.
25. Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ (2013) Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 28:170-181.
26. Gómez G, Calle ML, Oller R, Langohr K (2009) Tutorial on methods for interval-censored data and their implementation in R. Stat Model 9:259-297.
27. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X (2007) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61:911-922.
28. Groves JO (2007) Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12:1079-1088.
29. Gutierrez-Zotes JA, Bayon C, Montserrat C, Valero J, Labad A, Cloninger CR, Fernandez-Aranda F (2004) Temperament and character inventory revised (TCI-R). Standardization and normative data in a general population sample. Actas Esp Psiquiatr 32:8-15.
30. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A (2003) A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 25:277-283.
31. Höehne N, Poidinger M, Merz F, Pfister H, Brückl T, Zimmermann P, Uhr M, Holsboer F, Ising M (2014) FKBP5 genotype-dependent DNA methylation and mRNA regulation after psychosocial stress in remitted depression and healthy controls. Int J Neuropsychop. 18(4), doi: 10.1093/ijnp/pyu087.
32. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Callicott JH, Mattay VS, Weinberger DR, Meyer-Lindenberg A (2009) Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 45:44-51.
33. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression. New York: John Wiley and Sons.
34. Huckans M, Fuller B, Wheaton V, Jaehnert S, Ellis C, Kolessar M, Kriz D, Anderson JR, Berggren K, Olavarria H, Sasaki AW, Chang M, Flora KD, Loftis JM (2015) A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res 78:184-192.
35. Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF, Harris CR, Marini AM, Enoch MA, Lipsky RH (2005) BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30:1353-1361.
36. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S (2013) Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 11:6.
37. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, Rusanescu G, Yang L, Tian Y, Mao J (2012) Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 122:2940-2954.
38. Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch K-P, Scheurlen M (2007) Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132:1279-1286.
39. Krupoves A, Mack D, Deslandres C, Seidman E, Amre DK (2011) Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. Pharmacogenet Genomics 21:454-460.
40. Lang UE, Hellweg R, Sander T, Gallinat J (2009) The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 14:120-122.
41. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T, Kunz D, Gallinat J (2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 180:95-99.
42. Le Francois B, Czesak M, Steubl D, Albert PR (2008) Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55:977-985.
43. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR (2003) Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23:8788-8799.
44. Lok A, Mocking RJ, Ruhe HG, Visser I, Koeter MW, Assies J, Bockting CL, Olff M, Schene AH (2012) Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 37:892-902.
45. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG (2007) Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 63:131-135.
46. Lotrich FE, Albusaysi S, Ferrell RE (2012) Brain-Derived Neurotrophic Factor Serum Levels and Genotype: Association with Depression during Interferon-alpha Treatment. Neuropsychopharmacology 38:985-995.
47. Martín-Santos R, Díez-Quevedo C, Castellví P, Navinés R, Miquel M, Masnou H, Soler A, Ardevol M, García F, Galeras JA, Planas R, Solà R (2008) De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 27:257-265.
48. Martin-Santos R, Egmond E,Cavero M, Mariño Z, Navinés R, Forns X, Valdés M (2015) Chronic hepatitis C, depression and gender: a state of art. Adv Dual Diagn 8:193-210.
49. Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S, Uhr M, Holsboer F, Binder EB (2013) Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 12:289-296.
50. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, Weinberger DR, Berman KF (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 8:594-596.
51. Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18:595-606.
52. Muller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988-1000.
53. Navines R, Castellvi P, Moreno-Espana J, Gimenez D, Udina M, Canizares S, Diez-Quevedo C, Valdes M, Sola R, Martin-Santos R (2012) Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire. J Affect Disord 138:343-351.
54. Olsson I, Mykletun A, Dahl AA (2005) The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5:46, doi: 10.1186/1471-244X-5-46.
55. Perlman WR, Webster MJ, Kleinman JE, Weickert CS (2004) Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 56:844-852.
56. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR (2010) A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 51:137-148.
57. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005a) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19:105-123.
58. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH (2005b) Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66:41-48.
59. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B, Miller AH (2009) Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 65:296-303.
60. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH (2010a) Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 15:535-547.
61. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH (2010b) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15:393-403.
62. Robaeys G, De Bie J, Wichers MC, Bruckers L, Nevens F, Michielsen P, Van Ranst M, Buntinx F (2007) Early prediction of major depression in chronic hepatitis C patients during peginterferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol 13:5736-5740.
63. Schäfer A, Scheurlen M, Weissbrich B, Schöttker K, Kraus MR (2007) Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy 53:292-299.
64. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM (2012) Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 57:1379-1390.
65. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, Weder AB, Burmeister M (2003) A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28:397-401.
66. Silverman MN, Sternberg EM (2012) Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann NY Acad Sci 1261:55-63.
67. Smith AK, Simon JS, Gustafson EL, Noviello S, Cubells JF, Epstein MP, Devlin DJ, Qiu P, Albrecht JK, Brass CA, Sulkowski MS, McHutchinson JG, Miller AH (2012) Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry 17:781-789.
68. Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282:1737-1744.
69. Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Rajewska-Rager A, Dmitrzak-Weglarz M, Wilkosc M, Skibinska M, Hauser J (2011) Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. J Affect Disord 134:138-144.
70. Tchivileva IE, Nackley AG, Qian L, Wentworth S, Conrad M, Diatchenko LB (2009) Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase. Mol Pain 5:13.
71. Tournier BB, Steimer T, Millet P, Moulin-Sallanon M, Vallet P, Ibanez V, Ginovart N (2013) Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine. Int J Neuropsychop 16:1819-1834.
72. Tuominen L, Salo J, Hirvonen J, Nagren K, Laine P, Melartin T, Isometsa E, Viikari J, Cloninger CR, Raitakari O, Hietala J, Keltikangas-Jarvinen L (2013) Temperament, character and serotonin activity in the human brain: a positron emission tomography study based on a general population cohort. Psychol Med 43:881-894.
73. Turnbull BW (1976) The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Statist Soc B 38:290-295.
74. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, Langohr K, Sola R, Vieta E, Martin-Santos R (2012) Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 73:1128-1138.
75. Udina M, Moreno-Espana J, Navines R, Gimenez D, Langohr K, Gratacos M, Capuron L, de la Torre R, Sola R, Martin-Santos R (2013) Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 38:1803-1813.
76. Udina M, Hidalgo D, Navines R, Forns X, Sola R, Farre M, Capuron L, Vieta E, Martin-Santos R (2014) Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 75:e1113-1121.
77. Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK, Franke B (2010) Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15:260-271.
78. Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in Man[mdash]: a PET study with [11C] raclopride. Neuropsychopharmacology 20:424-433.
79. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R, Smit JH, Zitman FG, Penninx BW (2009) Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66:617-626.
80. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7:985-994, 924.
81. Zhang Y, Liu L, Liu YZ, Shen XL, Wu TY, Zhang T, Wang W, Wang YX, Jiang CL (2015) NLRP3 Inflammasome Mediates Chronic Mild Stress-induced Depression in Mice via Neuroinflammation. Int J Neuropsychop 18(8), doi: 10.1093/ijnp/pyv006
82. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370.